1. HOME
2. Research Insight
3. Product Launches was the Key Growth Strategy Adopted by Players Operating in the High Throughput Process Development Market

The high throughput process development market is highly competitive in nature. Some of the major players in this market include are Danaher Corporation (U.S.), GE Healthcare (U.S.), Agilent Technologies (U.S.), Merck Millipore (Germany), and Thermo Fisher Scientific (U.S.). The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include Tecan (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), and Sartorius Stedim Biotech Group (France).

Danaher Corporation is a global science and technology driven company that designs, manufactures, and markets medical, industrial, and commercial products and services. The company strategically concentrates on developing new and innovative products to strengthen its position in the global high throughput process development market. For instance, in April 2015, Molecular Devices, LLC (a subsidiary of Danaher Corporation) launched the SpectraMax i3x Multi-Mode Microplate Reader for in-depth cellular pathway analysis. For this purpose, the company significantly invests in R&D activities. In 2015, it invested 6.75% of its revenue in R&D activities. The company witnessed a 0.5% increase in its revenue from 2014 to 2015. The revenue growth is primarily attributed to the increase in the price of products offered in the process solutions business. It also focused on acquisitions to fortify its position in the market. In April 2014, Beckman Coulter, Inc., along with Cytojene Corporation (U.S.), acquired Xitogen Technologies Inc. (China), a flow cytometer developer. This acquisition helped the company to expand its business in the Asia-Pacific market.

GE Healthcare (U.S.) is another major player in the high throughput process development market. To strengthen its position in the market, the company strategically invests in product launches. For example, in April 2016, GE Healthcare launched UNICORN 7, a system control software used in research, process development, and manufacturing. Through this launch, the company expanded its product offering in the UNICORN software segment. In addition, GE Healthcare has also adopted inorganic strategies such as agreements. For example, GE Healthcare Life Sciences entered into an agreement with Zenith Technologies (Ireland), a company which delivers manufacturing execution systems (MES), automation, and process control excellence to life science companies across the globe. The agreement enabled GE Healthcare to integrate Zenith’s process control systems, MES, and other supporting technologies with its start-to-finish technologies and solutions to support biopharmaceutical manufacturing

Thermo Fisher Scientific Inc. (U.S.) is one of the leaders in serving science. In order to sustain its strong position in this market, the company mainly concentrates on product launches. For instance, in July 2016, the company launched the Axiom Precision Medicine Research Array for epidemiologists and genomics researchers. The company also focuses on inorganic growth strategies such as agreements to strengthen its market position in the HTPD market. For instance, in August 2016, the company signed a distribution agreement with Hamilton Bonaduz AG (Switzerland), a leading provider of manual and automated liquid handling, process measurement, and storage solutions for forensic applications. Under this agreement, Thermo Fisher will distribute Hamilton’s automation instruments and consumables in Europe, the Middle East, Africa, and China, and helped to strengthen its geographical presence.

Merck Millipore (Germany) is a leading company that offers a broad range of bioreactor systems and consumables for biomanufacturing. To strengthen its position in the life science industry, it acquired Sigma-Aldrich (U.S.), a multinational chemical, life science, and biotechnology company which enhanced its product portfolio, capabilities, and geographical presence.

The company strives to launch new products in order to strengthen its business position in the market. Besides the product launches, the company also focuses on other strategies such as expansions. In accordance with this, in January 2017, the company established its process development centers in Boston (U.S.) and Shanghai (China). These centers will provide a full range of process development services, which include cell line development services, both upstream and downstream process development, as well as non-GMP clinical production

Agilent Technologies, Inc. (U.S.) is one of the leading players in the HTPD market. It has been adopting organic as well as inorganic growth strategies to ensure its key position in the global market. The company is focusing on developing and introducing new technologies to the market. Agilent Technologies, Inc. launched a number of products to enhance their market share, namely, 1260 Infinity II LC system, a new core platform of the InfinityLab LC Series; 4200 TapeStation System, a fully automated system for higher throughput and quality screening; and upgraded its existing SurePrint gene expression assay.

Further, the company has entered into a number of agreements to enhance its technology offerings and strengthen its customer base. For instance, in November 2016, Agilent signed a co-marketing agreement with PureHoney Technologies, Inc. (U.S.) to develop new applications on its RapidFire 365 High-throughput Mass Spectrometry System. This development expanded the company’s product offering in the high-throughput mass spectrometry segment

Companies in the high throughput process development market are majorly focusing on product launches for strengthening their market share; this strategy accounted for 55.3% of the total number of strategic developments undertaken by key players in this market.

Related Reports:

High Throughput Process Development Market by Product & Service (Instrument, Software and Service), Molecule Type (Monoclonal Antibodies, Recombinant Insulin), Process (Upstream, Downstream), End User (Contract Manufacturing Organization) - Forecast to 2021

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: [email protected]